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Edited by Robert BaroukiAbstract The imidazoline BL11282 stimulates insulin release
and alters islet proteomes. Subcellular fractions of MIN6 cells
showed that the membrane fraction exhibited binding to
BL11282 on a Biacore chip and to BL11282-labelled magnetic
beads. Bound material extracted from the beads showed a
50 kDa diﬀerential band upon SDS–PAGE and a weaker
100 kDa band. The former was sensitive to competitive removal
by preincubation of the fraction with BL11282, then highlighting
the 100 kDa band. Masspectrometric analysis revealed the
50 kDa band to be EF1A and the 100 kDa band to be glucose
regulated P94, both of interest in insulin synthesis and secretion.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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A number of imidazoline compounds possess insulinotropic
activity [1,2] and are of special interest in type 2 diabetes, char-
acterized by insuﬃcient insulin secretion from the pancreatic
b-cell [3,4]. We have developed an imidazoline derivative
(BL11282) which increases insulin release only at high glucose
concentrations [3,5]. This is of particular interest in type 2 dia-
betes, since stimulation of insulin release at low or normal
blood glucose levels will cause risk of hyperinsulinemia and
thus resulting hypoglycemia. BL11282 has been selected as a
reference compound for evaluation of other pure glucose-
dependent insulinotropic compounds [6]. Therefore, the mech-
anisms underlying the insulin-releasing eﬀect of this compound
are of interest. Previously, we investigated proteome altera-
tions upon exposure of rat islets to BL11282 and found that
this drug has profound eﬀects on cellular pathways in pancre-
atic b-cells [7].
With the positive identiﬁcation of diﬀering proteins in
BL11282 exposed contra non-exposed cells established, we
decided to study whether we could ﬁnd BL11282 binding pro-*Corresponding author. Fax: +46 8 33 74 62.
E-mail address: Hans.Jornvall@ki.se (H. Jo¨rnvall).
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doi:10.1016/j.febslet.2008.04.007teins. In the present work, we used surface plasmon resonance
(SPR), a proteome extraction kit, and BL11282-labelled mag-
netic beads to selectively purify BL11282 binding proteins from
diﬀerent cellular compartments. In this manner, we found selec-
tive binding to membrane fractions and identiﬁed two binding
proteins. These proteins are involved in the same functional
system (protein synthesis and folding) as a number of the pro-
teins found by proteome analysis [7] to be diﬀerentially ex-
pressed in the BL11282 treated islets. Hence, two separate
analyses highlight particular protein systems of special interest.2. Materials and methods
2.1. Materials
BL11282 was modiﬁed to give a 3-aminopropargyl derivative
(Fig. 1) used for covalent attachment to prepare an aﬃnity medium.
The b-cell line MIN6 (passages 33–36) was cultured as described [8].
2.2. Protein extraction
MIN6 cells grown to 90% conﬂuence were extracted with ProteoEx-
tract subcellular proteome extraction kit (Calbiochem) into four
fractions (cytosolic, membranes, nuclear and matrix). Those cells
which were detached from the plate during the extraction procedure
were extracted as suspended cells according to the manufacturers pro-
tocol. The fractions obtained were frozen at 20 C in aliquots and
were used for analysis within a month. BL11282 binding activity in
the fractions was determined by SPR using a Biacore 3000 instrument
(GE Healthcare).
2.3. Surface plasmon resonance (SPR) measurements
Binding activities of sub-cellular fractions were determined in a Bia-
core 3000 instrument. The modiﬁed BL11282 compound was immobi-
lized on a CM5 sensor chip surface by amine coupling. In brief the chip
surface was ﬁrst washed for 1 min with 4 M LiCl and 0.2% surfactant
P20 (SP20) (Biacore) in Tris buﬀered saline (TBS). Two lanes on the
chip surface were activated according to the standard procedure with
an injection of 0.05 M N-hydroxysuccinimide (NHS)/0.2 M N-ethyl-
N 0-[3-dimethylamino)propyl]carbodiimide (EDC) HCl for 7 min at
5 ll/min. The modiﬁed BL11282 compound (40 lg/ml in 10 mM so-
dium acetate, pH 5) was immobilized on lane 2 at a ﬂow of 5 ll/min.
After immobilization both lanes were subjected to 1 M ethanolamine
to deactivate remaining activated carboxylic groups. Lane 1, only acti-
vated and deactivated (without addition of modiﬁed BL11282), was
used as control in the binding experiments. TBS containing 0.005%
SP20 was used as running buﬀer, and diﬀerent fractions were injected
at 10 ll/min for 2 min. The surface was regenerated after each cycle
with 6 M guanidine–HCl, pH 6.8, and frequently treated also with di-
luted trypsin in 20 mM ammonium bicarbonate, pH 8, to remove pro-
teins non-speciﬁcally adsorbed onto the chip surface.blished by Elsevier B.V. All rights reserved.
Fig. 1. Structures of BL11282 and the modiﬁed derivative used for the
labelling of the chips and magnetic beads.
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Fig. 2. SPR analysis of binding activity in the membrane fraction of
MIN6 cells (black line), after incubation with unlabelled (control)
beads (gray line) and after incubation with BL11282-labelled beads
(dashed line). All curves are after blank subtraction.
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For recovery of the BL11282 binding protein(s), magnetic Dynabe-
ads M-270 (Dynal Beads, Invitrogen) were activated with EDC/NHS
in a manner similar to that for the Biacore chips. In brief, the beads
were washed twice with 25 mM MES buﬀer, pH 5, after which freshly
dissolved EDC and NHS in MES buﬀer were added for 30 min at
room temperature. Excess EDC/NHS was removed by washing twice
with MES buﬀer. Subsequently, the activated beads were incubated
with the modiﬁed BL11282 (40 lg/ml) for 30 min at room temperature
during rotation. After incubation the unbound compound was re-
moved by washing twice for 15 min with TBS. Remaining activated
carboxylic groups on the beads were blocked by incubation with
1 M ethanolamine for 30 min, followed by washing with TBS for
3 · 15 min. For control experiments, beads activated with EDC/NHS
and deactivated with ethanolamine were used.
Membrane fractions prepared from MIN6 cells were incubated with
both labelled and unlabelled (control) beads for 4 h at room tempera-
ture. After incubation the beads were settled with the help of a magnet,
and the supernatant was transferred to a fresh tube. The beads were
then washed once with extraction buﬀer (F2) and twice with TBS for
15 min, and all supernatants were discarded. Bound material on the
beads was extracted, ﬁrst with 1 M NaCl for 15 min and then with
50 mM NaOH for 30 min at room temperature with rotation. In both
steps the beads were settled with a magnet and the supernatants col-
lected. Finally, the beads were boiled in 1 · SDS–PAGE sample buﬀer
to extract remaining bound proteins. All fractions (obtained with
NaCl, NaOH, and boiling) were analyzed on Bis-Tris SDS/PAGE
and silver-stained with Silverquest Kit (Invitrogen).
Competition experiments using Biacore and labelled beads were car-
ried out by pre-incubation of the membrane fraction with 0–5 mM of
free BL11282 for 1 h at room temperature.
2.5. In-gel digestion and mass spectrometry
The protein bands from the gels were excised manually and in-gel di-
gested with trypsin using a MassPrep robotic system (Waters) [9]. The
digests were concentrated under a stream of nitrogen and analyzed on
a Q-TOF Ultima API mass spectrometer (Waters) coupled on-line with
CapLC (Waters). The mass spectrometer was operated in positive ion
mode employing data-dependent acquisition over a mass range of 350–
2000 m/z. The sample was separated on a Waters Atlantis C18 column
(3 lm, 100 A˚, 75 lm · 150 mm) with a solvent system of 5% acetoni-trile/0.1% formic acid in water (solvent A) and 95% acetonitrile/0.1%
formic acid (solvent B) after desalting with a LC Packings Nanoease
Trapcolumn (300 lm ID · 1 mm; 5% acetonitrile/0.1% formic acid;
20 ll/min).The peptides were eluted with a linear gradient of 10–50%
solvent B for 20 min at 200 nl/min. Data analysis was performed using
ProteinLynx Global SERVER 2.1 (PLGS 2.1, Waters) software and
MassLynx peptide sequence software version 4.0 (Waters). Data sets
were analyzed using the NCBI BLAST and Mascot search engines
against Swissprot with the genomic database of Mus musculus chosen
for both search methods without constrictions regarding molecular
weight or pI. Mass spectra and sequences were manually examined
and conﬁrmed to be of suﬃcient quality for conﬁdent identiﬁcation.
Only sequences of at least eight residues were taken into consideration
and an Expect value 60.05 for at least one sequenced peptide was re-
quired for identiﬁcation.3. Results
3.1. Cellular fractionation and SPR analysis
BL11282 binding activity in diﬀerent fractions of MIN6 cells
was determined by SPR using a Biacore 3000 instrument. The
cells were fractionated into four parts, cytosolic, membrane,
nuclear and matrix, with a subcellular proteome extraction
kit, and binding activities were monitored for each fraction
(cf. [10]). Binding experiments were performed after fraction-
ation and then again after incubation of labelled beads or con-
trol beads (see below). Most of the binding activity was found
in the membrane fraction, while some was also detectable in
the cytosolic fraction. Although absolute binding varied be-
tween diﬀerent extractions, the membrane fraction was always
the one with higher binding than the cytosolic fraction. The net
binding (control lane extracted) was typically around 1000 re-
sponse units for the membrane fraction.
3.2. Binding experiments
For the identiﬁcation of binding proteins, BL11282-labelled
magnetic beads were employed. After incubation, supernatants
were recovered and monitored for binding in the Biacore
instrument. Fig. 2 shows a considerable loss of binding in
the supernatant of labelled beads, whereas only a little decrease
is observed in the supernatant of the control beads. Material
that was giving rise to the binding response in the BL11282-la-
belled lane of the SPR-chip is now apparently attached to the
Fig. 3. SDS–PAGE of the fractions extracted from the beads. 50 mM
NaOH extract of the unlabelled (lane 1) and labelled (lane 2) beads,
boiled extract of the unlabelled (lane 3), and labelled (lane 4) beads,
marker proteins (lane 5).
Fig. 4. SDS–PAGE of the fractions obtained after competition
experiments (pre-incubation with 1 mM BL11282) before incubation
with labelled or unlabelled beads. 50 mMNaOH extract of the labelled
(lane 1) and unlabelled (lane 2) beads, boiled extract of the labelled
(lane 3), and unlabelled (lane 4) beads, marker proteins (lane 5).
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boiling, showed various bands on SDS–PAGE but a strong
band of about 50 kDa was speciﬁcally present in diﬀerent
MIN6 cell preparations (Fig. 3). The presence of a weak
100 kDa band was also observed (Fig. 3). These bands were
identiﬁed by peptide masspectrometric analysis after digestion
(below).
3.3. Competition experiments
Competition experiments were performed by pre-incubation
of the membrane fraction with free BL11282. In Biacore anal-
ysis, the presence of the free compound failed to compete with
the binding, while the bead extracts, after competition with
1 mM free compound showed removal of the 50 kDa band,
resulting in the 100 kDa band as the strongest one seen
(Fig. 4).
3.4. Mass spectrometric identiﬁcations
The tryptic peptides of the two protein bands identiﬁed in
the binding experiments were analyzed by LC–MS/MS. The
50 kDa band was identiﬁed as elongation factor 1 alphaTable 1
Identiﬁcation of protein bands by MS/MS sequence analysis of tryptic pepti
Protein Accession number (swissprot)
eEF1A-1/2a (50 kDa) P10126
P62631
GRP94 (100 kDa) P08113
aVariants 1 and 2 of eEF1A diﬀer at positions outside those now analyzed.
bIdentiﬁed by mass only (too weak for sequence analysis).(eEF1A) by recovery of the sequence of three peptides, and
the 100 kDa band was identiﬁed by the Mascot search engine
(signiﬁcance threshold p = 0.05) as glucose regulated protein
94 (GRP94). Two peptide sequences and an additional mass
corresponding to a third peptide were recovered from the
100 kDa band (Table 1).4. Discussion
Using sub-cellular fractionation, SPR-binding studies and
aﬃnity puriﬁcation on BL11282-labelled beads, we have iden-
tiﬁed two binding proteins in a mouse insulinoma cell line. Ex-
tracts from the cell line showed the presence of clear binding to
BL11282-labelled SPR-chips, which disappeared upon incuba-
tion with BL11282-labelled beads. In competition binding
experiments using SPR measurements, the presence of free
compound (in concentration up to 1 mM) did not compete,
presumably because the BL11282 derivative on the Biacore
chips is highly available. However, in competition experimentsdes
Peptide sequence Position Expect value
LPLQDVYK 248–255 0.03
IGGIGTVPVGR 256–266 0.083
QTVAVGVIK 431–439 0.026
TDDEVVQR 44–51 1.0
ELISNASDALDK 103–114 0.007
EVEEDEYKb 349–356 4.3
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with 1 mM free compound, the eEF1A band was competitively
removed and the 100 kDa GRP94 band then emerged as the
strongest band (Fig. 4). The appearance of the GRP94 band in
the bead experiments after competitive removal of eEF1A
shows that GRP94 has a diﬀerent mode of binding than
eEF1A with BL11282. In a previous report we have studied
proteomes of rat pancreatic islets by a 2-D gel approach and
did then not ﬁnd eEF1A and GRP94 [7]. However, because
of the low abundance of these proteins even in the present
aﬃnity-enriched preparations (Fig. 3), their absence of detec-
tion in overall proteome 2-D gel comparisons is not surprising.
In type 2 diabetes the inadequate insulin release requires an
extra stimulus to secrete more insulin which is usually accom-
plished by the sulfonylurea drugs but with a risk of severe
hypoglycemia [11]. BL11282, unlike sulfonylurea, stimulates
glucose dependent insulin release and not insulin release at ba-
sal glucose levels, thus the risk of hypoglycemia is reduced
[3,5]. A pure glucose-dependent insulinotropic activity of
BL11282 involves the KATP channel independent pathways
of stimulation of insulin secretion, the nature of which are still
not fully understood. The identiﬁcations of eEF1A and
GRP94 as BL11282 binding proteins, point to possible mech-
anisms involved in BL11282-stimulated insulin secretion.
EF1A has a major function in delivery of aminoacyl-tRNA
to the ribosome but it also possesses many other functions like
stabilization of the microtubules in a Ca2+/calmodulin-depen-
dent manner [12] and in the regulation of the actin cytoskele-
ton and cell morphology [13]. It has been reported that
biosynthesis of insulin is controlled at the translational level
[14] and the translation of mRNA encoding insulin is preferen-
tially increased in pancreatic b-cells by glucose stimulation
[15]. In a recent report control of mRNA translation through
phosphorylation of eukaryotic initiation factor 2 (eIF2a) has
been found essential for the increased insulin production
[16]. It has also been demonstrated that EF1A is a potential
associated binding partner for Akt/PKB [17], a protein kinase
involved in regulation of insulin secretion [18].
GRP94 is a molecular chaperone in the endoplasmic reticu-
lum (ER) where it is known to bind ATP, peptides [19] and
Ca2+ [20]. Its role in maturation and transport of thyroglobu-
lin along the secretory pathway has been reported [21].
Although a role of GRP94 in the synthesis of insulin is not
ﬁrmly established, maturation of proinsulin in the ER of the
b-cells may well require GRP94 [22], and a decrease in
GRP94 is accompanied by a loss of glucose-responsiveness
in insulin-secreting cells [23].
In conclusion, our results suggest that BL11282 binds to
elongation factor 1 alpha and to GRP94 in insulin-secreting
cells, both proteins of interest in insulin synthesis and secretion.
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